Artificial organs

As surgeries resume, pediatric cochlear implantation can now be done as young as 9 months

Retrieved on: 
Tuesday, May 19, 2020
Audiology, Hearing, Perception, Articles, Otology, Cochlear, Artificial organs, Bionics, Neuroprosthetics, Implant, Cochlea, Hearing loss

* This FDA approval is extended to all current Cochlear Nucleus Implant models, as well as all models developed in the future by Cochlear.

Key Points: 
  • * This FDA approval is extended to all current Cochlear Nucleus Implant models, as well as all models developed in the future by Cochlear.
  • For more clinical information on the longitudinal outcomes of cochlear implantation for children with hearing impairment, visit: www.outcomes.nal.gov.au/key-findings .
  • Leigh J, Dettman S, Dowell R. Evidence-based guidelines for recommending cochlear implantation for young children: Audiological criteria and optimizing age at implantation.
  • And always and other trademarks and registered trademarks are the property of Cochlear Limited or Cochlear Bone Anchored Solutions AB.

VisionCare, Inc. Announces CE Mark Approval of the Tsert-SI™ Delivery System for the CentraSight Treatment Program

Retrieved on: 
Monday, May 11, 2020
Health, Consumer, Surgery, Seniors, General Health, Optical, Biotechnology, Medical technology, Prosthetics, Technology, Biotechnology, Emerging technologies, Medical devices, Artificial organs, Eye, Visual prosthesis, Implant, Macular degeneration, Yossi Gross

VisionCare, Inc. ("VisionCare), a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced that receipt of a Conformit Europene (CE) Mark for the Tsert-SI delivery system for the CentraSight treatment program.

Key Points: 
  • VisionCare, Inc. ("VisionCare), a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced that receipt of a Conformit Europene (CE) Mark for the Tsert-SI delivery system for the CentraSight treatment program.
  • The CentraSight treatment program includes the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), which is available around the world, including the United States, Europe, Australia, New Zealand, and Israel.
  • The Tsert-SI delivery system includes a pre-loaded telescope implant injector, which only requires a 6.5mm incision, reducing the incision size by nearly half.
  • Patients and physicians can find more information about the telescope implant and related treatment program by visiting www.CentraSight.com or calling 1-877-997-4448.

FDA expedites approval of Cochlear's Remote Check solution for cochlear implants

Retrieved on: 
Tuesday, April 7, 2020
Audiology, Medical technology, Medicine, Health, Otology, Medical devices, Artificial organs, Bionics, Cochlear Bone Anchored Solutions, Cochlear, Hearing loss, Implant

CENTENNIAL, Colo., April 7, 2020 /PRNewswire/ --Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval on April 2 for its Remote Check solution.

Key Points: 
  • CENTENNIAL, Colo., April 7, 2020 /PRNewswire/ --Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval on April 2 for its Remote Check solution.
  • Remote Check will ensure that patients receive the best care no matter where life and times like this take us."
  • Products include cochlear implants, bone conduction implants and acoustic implants, which healthcare professionals use to treat a range of moderate to profound types of hearing loss.
  • And always and other trademarks and registered trademarks are the property of Cochlear Limited or Cochlear Bone Anchored Solutions AB.

Cochlear reveals winners of annual flagship scholarship programs

Retrieved on: 
Monday, January 27, 2020
Medical technology, Hearing, Cochlear, Perception, Artificial organs, Audiology, Bionics, Neuroprosthetics, Otology, Graeme Clark, Implant, Cochlea

CENTENNIAL, Colo., Jan. 27, 2020 /PRNewswire/ -- Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announced today the winners of the 18th annual Graeme Clarkand the ninth annual Anders Tjellstrmscholarships.

Key Points: 
  • CENTENNIAL, Colo., Jan. 27, 2020 /PRNewswire/ -- Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announced today the winners of the 18th annual Graeme Clarkand the ninth annual Anders Tjellstrmscholarships.
  • The Graeme Clark Scholarship is named after Professor Graeme Clark, the inventor and pioneer of the multichannel cochlear implant.
  • An esteemed panel of judges helped review and select the scholarship winners, including:
    For more information about the scholarships, visit Cochlear.com/us/scholarship .
  • And always and other trademarks and registered trademarks are the property of Cochlear Limited or Cochlear Bone Anchored Solutions AB.

Bionic Vision Technologies Announces Interim Pilot Study Results of the BVT Bionic Eye System Designed to Help the Blind Achieve Greater Mobility and Independence

Retrieved on: 
Monday, January 13, 2020
Medical technology, Medicine, Articles, Emerging technologies, Neuroprosthetics, Medical devices, Biological engineering, Artificial organs, Visual prosthesis, Retinitis pigmentosa, Retinitis, Retina

Each study participant was unilaterally implanted with the BVT Gen2 suprachoroidal visual prosthesis in the eye with the least remaining vision.

Key Points: 
  • Each study participant was unilaterally implanted with the BVT Gen2 suprachoroidal visual prosthesis in the eye with the least remaining vision.
  • Mobility testing was initiated after a two-month surgical healing period followed by a 16-week period of vision rehabilitation training.
  • BVT is now developing the Gen3 Bionic Eye System which will incorporate new software algorithms, including automatically adjusting to environmental lighting conditions.
  • Bionic Vision Technologies, Pty., Ltd. (BVT) is a privately held Australian company developing the Bionic Eye System, a visual prothesis designed to restore functional vision to the blind suffering from inherited retinal diseases, such as Retinitis Pigmentosa (RP).

iotaMotion Submits De Novo Application To FDA For iotaSOFT™ Cochlear Implant Insertion System

Retrieved on: 
Monday, December 23, 2019
Audiology, Medical technology, Medicine, Articles, Otology, Artificial organs, Bionics, Neuroprosthetics, Cochlear implant, Cochlear, Implant, Hearing loss

The iotaSOFT system is intended to aid surgeons in the placement of cochlear implant electrode arrays.

Key Points: 
  • The iotaSOFT system is intended to aid surgeons in the placement of cochlear implant electrode arrays.
  • Currently, a significant percentage of hearing preservation cochlear implant patients still suffer from hearing loss over time.
  • "Alongside our De Novo application, we are planning initial commercial activities for an impactful launch led by some of the world's leading experts in cochlear implant surgery, once the FDA has authorized."
  • The iotaSOFT system will allow surgeons to advance cochlear implant electrodes with the control and precision of computers.

Worldwide Cochlear Implant Markets, 2018 to 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 9, 2019
Medical devices, Health, Medical technology, Medicine, Otology, Medical specialties, Auditory system, Prosthetics, Medical devices, Artificial organs, Cochlear implant, Implant, Cochlea, Neuroprosthetics

Valued at nearly $1.2bn in 2018, the Cochlear Implants Market is growing at a healthy pace - in the upper single-digits, at a compound annual growth rate (CAGR) of approximately 9%.

Key Points: 
  • Valued at nearly $1.2bn in 2018, the Cochlear Implants Market is growing at a healthy pace - in the upper single-digits, at a compound annual growth rate (CAGR) of approximately 9%.
  • Cochlear implants are one of the most successful neural prosthesis to date; yet, it is still a substantially underpenetrated market.
  • The cochlear implants market will also be driven by a long/established clinical history, strong benefits vs. risks, technological innovations, aggressive sales/marketing and education efforts, and increasing audiology practice referrals.
  • The cochlear implants market is substantial, totaling nearly $1.2bn in 2018 and forecast to grow at a healthy rate of 8%-10%.

iotaMotion Completes Initial Usability Study And Raises $2.52 Million In Second Round Of Funding

Retrieved on: 
Wednesday, August 28, 2019
Medicine, Medical specialties, Audiology, Medical technology, Otology, Neuroprosthetics, Artificial organs, Cochlear, Implant, Otorhinolaryngology, Hearing loss

iotaMotion also announces the successful completion of the iotaSOFT human-factors usability study, held in July with participation from leading cochlear implant surgeons in a simulated use clinical environment.

Key Points: 
  • iotaMotion also announces the successful completion of the iotaSOFT human-factors usability study, held in July with participation from leading cochlear implant surgeons in a simulated use clinical environment.
  • The Company's technology will enable surgeons to achieve more precise, effective solutions for patients experiencing various types of hearing loss.
  • "We're pleased to have completed this second round of friends-and-family financing with participation from both existing and new investors," said Chris Kaufmann, MD, President and co-founder of iotaMotion.
  • A privately-held Iowa based company, iotaMotion is developing robotic technologies with the goal of focused, individualized, hearing loss treatment.

World Neuroprosthetics Market Forecast to 2025 - Focus on Cochlear Implants, Bionic Eye/Retinal Implants, Motor Prosthetics, and Cognitive Prosthetics

Retrieved on: 
Thursday, August 8, 2019
Medical technology, Articles, Technology, Audiology, Artificial organs, Medical devices, Cochlear implant, Cybernetics, Neuroprosthetics, Implant

Neuroprosthetics market worldwide is projected to grow by US$8.3 Billion, guided by a compounded growth of 12.5%.

Key Points: 
  • Neuroprosthetics market worldwide is projected to grow by US$8.3 Billion, guided by a compounded growth of 12.5%.
  • Cochlear Implants, one of the segments analyzed and sized in this study, displays the potential to grow at over 12.4%.
  • Poised to reach over US$3.7 Billion by the year 2025, Cochlear Implants will bring in healthy gains adding significant momentum to global growth.
  • In Japan, Cochlear Implants will reach a market size of US$251.7 Million by the close of the analysis period.

Global Neuroprosthetics Markets, 2019-2025: Cochlear Implants Market Poised to Reach Over US$3.7 Billion by 2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 8, 2019
Health, General Health, Medical technology, Articles, Technology, Audiology, Artificial organs, Medical devices, Cochlear implant, Cybernetics, Neuroprosthetics, Implant

Neuroprosthetics market worldwide is projected to grow by US$8.3 Billion, guided by a compounded growth of 12.5%.

Key Points: 
  • Neuroprosthetics market worldwide is projected to grow by US$8.3 Billion, guided by a compounded growth of 12.5%.
  • Cochlear Implants, one of the segments analyzed and sized in this study, displays the potential to grow at over 12.4%.
  • Poised to reach over US$3.7 Billion by the year 2025, Cochlear Implants will bring in healthy gains adding significant momentum to global growth.
  • In Japan, Cochlear Implants will reach a market size of US$251.7 Million by the close of the analysis period.